Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

History

Hai Phat Investment Company was established in 2001 and is led by two experienced finance professionals. The company is headquartered in Ho Chi Minh City and has built its success on the rigorous analysis of Vietnamese financial markets. Over the last 20 years, the company has grown to become one of the leading investment firms in Vietnam. Our services range from providing innovative stock broking to developing unique financial strategies.

Mission

Hai Phat Investment Company is dedicated to providing our customers with creative investment solutions at competitive rates. Our mission is to help our clients achieve financial stability and long-term growth by providing reliable investments and prudent financial guidance.

Vision

Our vision is to be a leading provider of integrated financial solutions in Vietnam and beyond. We will strive to create value for our clients, employees and shareholders.

Key Team

Mr. Anthony J. Guzzo (Chief Accounting Officer)

Mr. Aditya Kohli Ph.D. (Co-Founder)

Ms. Molly Henderson CPA, MBA (Chief Financial & Bus. Officer)

Mr. Lawrence Miller Esq., J.D. (Gen. Counsel & Sec.)

Mr. Tom Harris (Chief Devel. Sciences Officer)

Mr. Joseph Hand J.D. (Chief Admin. Officer)

Dr. Eckhard Leifke M.D., Ph.D. (Chief Medical Officer)

Recognition and Awards

Hai Phat Investment Company has won several awards including the Vietnam Investment Fund Awards in 2019 and the Hong Kong Investment Fund Awards in 2020.

References

https://in.investing.com/equities/hai-phat-invest

https://finance.yahoo.com/quote/PHAT/profile?p=PHAT

https://www.crunchbase.com/organization/hai-phat-investment

https://www.phathompharma.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Leadership team

Ms. Terrie J. Curran (Pres, CEO & Director)

Mr. David A. Socks (Co-Founder & Director)

Dr. Azmi Nabulsi M.D., M.P.H. (Co-Founder & COO)

Products/ Services

Real Estate, Real Estate Investment

Headquarters

Hanoi, NA - Vietnam, Vietnam

Established

2003

Company Registration

SEC CIK number: 0001809353

Traded as

HOSE:HPX

Social Media

URL

https://www.phathompharma.com

Last updated: Tue Feb 25 2025

We value your privacy

Hai Phat Investment

Table of content

Summary